33.78 USD
+0.35
1.05%
At close Jan 21, 4:00 PM EST
After hours
33.76
-0.02
0.06%
1 day
1.05%
5 days
4.84%
1 month
-0.82%
3 months
-11.48%
6 months
-14.24%
Year to date
-0.50%
1 year
-14.55%
5 years
-43.11%
10 years
-39.56%
 

About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Employees: 70,200

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

93% more call options, than puts

Call options by funds: $200M | Put options by funds: $104M

33% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 67

1% more funds holding

Funds holding: 871 [Q2] → 882 (+11) [Q3]

2% more capital invested

Capital invested by funds: $12.4B [Q2] → $12.7B (+$257M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q2] → 10 (+0) [Q3]

0.32% less ownership

Funds ownership: 7.8% [Q2] → 7.48% (-0.32%) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 302 | Existing positions reduced: 316

Research analyst outlook

We haven’t received any recent analyst ratings for GSK.

Financial journalist opinion

Based on 19 articles about GSK published over the past 30 days

Positive
CNBC
5 hours ago
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Positive
Zacks Investment Research
9 hours ago
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
Positive
VentureBeat
1 week ago
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Positive
CNBC
1 week ago
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care Conference.
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
Neutral
Zacks Investment Research
1 week ago
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
Neutral
Seeking Alpha
1 week ago
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer David Redfern - President Corporate Development Conference Call Participants James Gordon - JPMorgan James Gordon Good morning.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Positive
Yahoo Finance
1 week ago
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Healthcare sector poised for rebound in 2025
Positive
Seeking Alpha
1 week ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Positive
CNBC Television
1 week ago
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
GSK CEO on acquisition of biotech firm IDRx
Positive
Reuters
1 week ago
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Drugmakers rush to sign deals on first day of industry conference
Charts implemented using Lightweight Charts™